The cards separate the fund's live record from the longer factor history used for the backtest, then show model fit, cost, valuation, and risk-adjusted results.
Age
5.2 years
2021-Jun → 2026-Aug
Established live fund
Backtest Basis
63.0 years
1963-Jul → 2026-Jun
Full long-run factor record
Adj. R²
0.978
Very high model fit
AUM
US$13.1B
Very large live fund
MER
0.28%
Low-cost active tilt
Dividend valuation
105
Somewhat rich
105
80 90 100 110 120+
1.33% Current recurring yield
100 = median · below 100 inexpensive · above 100 rich Dividend valuation scale
Backtested Rel. Sharpe
1.35×
Decisive edge
R
0.5 1.0 1.3 1.8
Relative to a plain market benchmark. 1.0 = market-like risk-adjusted return; above 1.0 clears the market hurdle.
Smart-β Net
+4.64%
Strong positive value-add
S
-3% 0% 2.5% 4.5%
Annualized non-market factor contribution plus alpha. Above 0% means the smart-beta sleeve added value over plain market exposure.
Implementation: Core equity. No deterministic enhanced-income or derivative-income mandate detected.

What DFAT Is

DFAT (Dimensional U.S. Targeted Value ETF) from Dimensional is a US equity ETF with $13.1B in assets, regressed on the FF6 US over 60 months. The fund tilts toward size (smb) (β=0.87); tilts toward value (hml) (β=0.41); tilts toward profitability (rmw) (β=0.24). Backtested-simulation excess return is +10.84% annualized; the in-sample realized excess was +7.20%.

Why DFAT Ranks This Way

  • Backtested relative Sharpe is 1.35, above the market's 1.00 benchmark.
  • Realized relative Sharpe is 0.69 over the fund's 60-month live sample.
  • Strongest non-market tilts point toward size (smb) (β=0.87) and toward value (hml) (β=0.41).
  • Dividend valuation is near its historical median at 105 on the 100 scale.
Best-fit classification
US Equity FF6 US Regression basis: USD Adj. R² 0.978 Fit window: 60M Backtest basis: 756M

This fund is classified as US Equity because that factor set produced the strongest accepted fit. Backtested figures use the winning model's full factor history (1963-Jul → 2026-Jun, 756 months), while the betas themselves are estimated over the fund-overlap window (60 months).

Factor return decomposition
Each bar = βi × factor return, geometrically annualized. Summary rows are computed from the combined monthly series they name.
Model: FF6 US
Sharpe — Backtested Sim.
0.561
Rel. to market: 1.348
Sharpe — Realized
0.357
Rel. to market: 0.688
How are these computed?

Currency basis: returns and factor contributions on this page are in USD. Fama-French US 6-factor set (Ken French data library, monthly, USD basis).

Classification winner: FF6 US with Adj. R² 0.978.

Factor context panel: each non-market row compares the current fund with stronger-fit public peers using FF6 US. Beta mode shows raw loadings, percentile mode ranks the fund within the positive-exposure subset, and the linked ticker points to the strongest peer in that factor.

Backtested Sim. applies DFAT's regression betas to the full factor history (1963-Jul → 2026-Jun, 756 months). Individual factor bars show separately annualized sleeves, while the subtotal rows are computed from the combined monthly non-market and smart-beta series directly. The Sharpe uses DFAT's realized in-sample volatility as the denominator — a deliberately conservative choice, since fixed-loading factor returns are smoother than what any real fund actually delivers.

Realized applies the same betas to the factor returns observed during DFAT's lifetime only (2021-Jul → 2026-Jun). The Sharpe is the fund's actual excess return over its actual volatility. Full methodology →

Factor exposure context
Each non-market row compares this fund with stronger-fit public peers using FF6 US. Toggle between raw factor beta and percentile rank within the same positive-exposure peer set.
Compared against 329 funds using FF6 US
Peer filter: Equity · AUM floor · 24M+ history · Adj. R² > 0.80 · |βmkt−1| < 0.25 · Non-Mkt > 0
Default view is percentile rank. Switch to β scale when you want the raw loading magnitude.
SMB
-0.30
0
0.24
0.47
0.71
0.95
0
20
40
60
80
90
100
0
2
4
6
8
10
12
β +0.87
89th pct
t +18.9
Current fund: 89th percentile of positive peers · Top decile begins at β +0.88 · Leader: RZV
HML
-0.30
0
0.24
0.47
0.71
0.95
0
20
40
60
80
90
100
0
2
4
6
8
10
12
β +0.41
91st pct
t +8.4
Current fund: 91st percentile of positive peers · Top decile begins at β +0.40 · Leader: KBWB
RMW
-0.30
0
0.24
0.47
0.71
0.95
0
20
40
60
80
90
100
0
2
4
6
8
10
12
β +0.24
81st pct
t +5.6
Current fund: 81st percentile of positive peers · Top decile begins at β +0.28 · Leader: QVAL
CMA
-0.30
0
0.24
0.47
0.71
0.95
0
20
40
60
80
90
100
0
2
4
6
8
10
12
β +0.05
30th pct
t +0.8
Current fund: 30th percentile of positive peers · Top decile begins at β +0.23 · Leader: RWJ
UMD
-0.30
0
0.24
0.47
0.71
0.95
0
20
40
60
80
90
100
0
2
4
6
8
10
12
β -0.04
rank n/a
t -1.3
Current fund: non-positive loading · Top decile begins at β +0.17 · Leader: MTUM
Factor exposures
Factor β t-stat Backtested % Realized %
Size (SMB) 0.868 18.91 +1.54% -4.65%
Value (HML) 0.406 8.43 +1.38% +2.72%
Profitability (RMW) 0.242 5.65 +0.68% +0.33%
Investment (CMA) 0.050 0.84 +0.15% +0.06%
Momentum (UMD) -0.042 -1.29 -0.31% -0.35%
Non-Market Factor Contribution · combined non-market series +3.50% -2.15%
Alpha (intercept) 0.76 +1.11%
Smart-Beta Net · combined non-market series + alpha +4.64% -1.06%
+ Mkt-RF contribution · market 0.998 38.70 +6.16% +8.33%
= Total excess return +10.84% +7.20%
+ Rf base (%) 4.44% → 15.28% total 3.51% → 10.71% total
Fund snapshot
Issuer
Dimensional
Asset class
Equity
Inception
1998-12-11
Dividend yield
1.33%
Div CAGR
12.89%
Dividend valuation
105 (100=median)
Embed this chart

Use this iframe URL on Discourse forums (e.g. Rational Reminder Community) or any site that allows iframe embeds. For X, Reddit, or Slack, paste the fund page URL directly — the social card image is auto-generated for this fund.

<iframe src="https://verifiedbeta.com/embed/us/DFAT/waterfall/" width="720" height="540" style="border:0;" loading="lazy"></iframe>

These funds share the same statistically significant, material FF6 non-market factor set as DFAT. Broad-market funds are excluded unless they have verified factor exposure.

SLYV
94
Near substitute
DFSV
SMB HML RMW shape 100 · level 91
Compare DFAT vs DFSV
93
Near substitute
CSB
90
Verified similar
DES
87
Verified similar
AVUV
SMB HML RMW shape 100 · level 86
Compare DFAT vs AVUV
87
Verified similar
XMVM
86
Verified similar

3 additional factor-similar ETFs are held back for the future comparison view.

View full DFAT similarity cluster
All US Leaders US Universe Methodology

FAQ

What does this DFAT ETF page measure?

This page evaluates DFAT using factor regressions, relative Sharpe, valuation, and peer context. It is designed for ETF due diligence rather than quote tracking.

Why can Backtested Sim. and Realized differ?

Both views use the same estimated betas. The difference is the return window: Backtested Sim. applies them to the full factor history, while Realized applies them only during the fund's live sample.

Why might a high-return fund still look weak here?

A fund can post strong raw returns and still look unattractive on this screen if its non-market factor capture is weak, its implementation drag is high, or its volatility-adjusted return profile is weaker than the market.

How should US investors use this page?

Use it as a starting point for ETF selection: check whether the fund's live behavior, valuation, and peer context match its stated strategy.

Research disclaimer

Factor decomposition shows what DFAT's historical betas would have earned under each scenario — not a forecast, not investment advice. Backtested simulation assumes loadings stay fixed across the long sample, which is unrealistic for any real-world fund. Use this as one input to ETF due diligence, not a substitute for it.

Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.